CAM
TNDM icon

Cresset Asset Management’s Tandem Diabetes Care TNDM Stock Holding History

Cresset Asset Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Sell
11,112
-1,506
-12% -$26.3K ﹤0.01% 1609
2026
Q1 		$242K Buy
+12,618
New +$274K ﹤0.01% 1381
2025
Q1 		– Sell
-7,644
Closed -$275K – 1855
2024
Q4 		$275K Sell
7,644
-23,808
-76% -$805K ﹤0.01% 1403
2024
Q3 		$1.33M Buy
31,452
+1,569
+5% +$66.5K 0.01% 1017
2024
Q2 		$1.2M Buy
29,883
+1,697
+6% +$70.8K 0.01% 971
2024
Q1 		$998K Buy
28,186
+10,586
+60% +$284K ﹤0.01% 981
2023
Q4 		$521K Buy
+17,600
New +$365K ﹤0.01% 1211
2022
Q4 		– Sell
-7,460
Closed -$403K – 885
2022
Q3 		$403K Sell
7,460
-40
-0.5% -$2.19K 0.01% 573
2022
Q2 		$444K Buy
7,500
+671
+10% +$55.1K 0.01% 597
2022
Q1 		$794K Sell
6,829
-410
-6% -$47.9K 0.01% 465
2021
Q4 		$1.09M Buy
7,239
+1,239
+21% +$167K 0.01% 430
2021
Q3 		$716K Hold
6,000
– – 0.01% 498
2021
Q2 		$584K Buy
+6,000
New +$535K 0.01% 513

Other funds holding TNDM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Cresset Asset Management's TNDM Position: Q2 2026 in Review

Cresset Asset Management reduced its Tandem Diabetes Care (TNDM) stake by 12% in Q2 2026, selling an estimated $26.3K and leaving 11,112 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #1609.

Cresset Asset Management first reported a position in TNDM in Q2 2021 and has held it in 13 quarters since. The position peaked at $1.33M in Q3 2024. 274 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.

  • Cresset Asset Management held 11,112 shares of Tandem Diabetes Care worth $168K as of Q2 2026.
  • Cresset Asset Management sold 1,506 Tandem Diabetes Care shares in Q2 2026, an estimated $26.3K.
  • Tandem Diabetes Care made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1609 holding.
  • Cresset Asset Management first reported a position in Tandem Diabetes Care in Q2 2021 and has held it in 13 quarters since.
  • Cresset Asset Management's Tandem Diabetes Care position peaked at $1.33M in Q3 2024.
  • 274 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.